OncoSec Medical names new CEO | Personnel Moves – Nov. 9, 2017

This article was originally published here

OncoSec MedicalOncoSec Medical (NSDQ:ONCS)  announced earlier this week that the company’s co-founder, Punit Dhillon, would step down as CEO and continue to serve as president while Daniel O’Connor takes over the corner office.

O’Connor joined OncoSec’s board of directors in September this year.

“We are pleased to welcome Dan to OncoSec at this important time, and believe he is uniquely qualified to lead the company through the successful completion of its phase IIb registration directed trial, Pisces/Keynote-695 in patients with unresectable metastatic melanoma who have progressed or are progressing on an anti-PD-1 therapy,” chairman Avtar Dhillon said in prepared remarks. “Dan is a proven leader with a strong track record of success and brings exceptional strategic and operational expertise in building thriving, successful biopharma companies.”

Get the full story at our sister site, Drug Delivery Business News.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply